Total pharma industry M&A deals in Q1 2019 worth $127.86bn were announced in the US, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 962.3% over the previous quarter and a rise of 643.02% when compared with the last four-quarter average of $17.21bn.

The US held a 93.9% share of the global pharma industry M&A deal value that totalled $136.23bn in Q1 2019.

In terms of deal activity, the US recorded 54 deals during Q1 2019, marking a decrease of 27% over the previous quarter and a drop of 6.9% over the last four-quarter average.

The US pharma industry M&A deals in Q1 2019: Top deals

The top five pharma industry M&A deals accounted for 97.7% of the overall value during Q1 2019.

The combined value of the top five pharma industry M&A deals stood at $124.94bn, against the overall value of $127.86bn recorded for the quarter. The top announced pharma industry M&A deal tracked by GlobalData in Q1 2019 was Bristol-Myers Squibb ‘s $89.54bn acquisition of Celgene .

In second place was the $21.4bn asset transaction with General Electric by Danaher and in third place was Eli Lilly’s $8bn acquisition of Loxo Oncology .

The $4.3bn acquisition of Spark Therapeutics by F. Hoffmann-La Roche and Thermo Fisher Scientific ‘s acquisition of Brammer Bio for $1.7bn held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.